In these cases, as it is observed in cHL, NK cells become an efficient weapon against tumor cells, again supporting the non-neglectable benefits of PD-1/PD-L1-targeting therapies in cHL patients (145). This evidence concerns the gene CD274 and classic Hodgkin lymphoma.